Join
Live feed
·
PRReleasevia Quantisnow
Cytokinetics Incorporated logo

Cytokinetics Announces Start of MAPLE-HCM, a Phase 3 Clinical Trial of Aficamten Compared to Metoprolol in Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy

ByQuantisnow·Wall Street's wire, on your screen.
CYTK· Cytokinetics Incorporated
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track CYTK (Cytokinetics Incorporated) and more on Quantisnow.